JP2023522198A - 黒色腫を治療するためのｃｔｌ抗原の融合タンパク質 - Google Patents

黒色腫を治療するためのｃｔｌ抗原の融合タンパク質 Download PDF

Info

Publication number
JP2023522198A
JP2023522198A JP2022562788A JP2022562788A JP2023522198A JP 2023522198 A JP2023522198 A JP 2023522198A JP 2022562788 A JP2022562788 A JP 2022562788A JP 2022562788 A JP2022562788 A JP 2022562788A JP 2023522198 A JP2023522198 A JP 2023522198A
Authority
JP
Japan
Prior art keywords
seq
clt
fusion protein
antigen
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522198A5 (https=
JPWO2021212123A5 (https=
Inventor
カシオティス ジョージ
ヤング ジョージ
アッティグ ジャン
スナイデルス アンブロジウス
パーキンス デイビッド
マリノ ファビオ
ジュップ レイ
ボン エッセン マグダリーナ
メイソン ピーター
ターネット ニコラ
Original Assignee
ザ フランシス クリック インスティチュート リミティッド
エナラ バイオ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ フランシス クリック インスティチュート リミティッド, エナラ バイオ リミテッド filed Critical ザ フランシス クリック インスティチュート リミティッド
Publication of JP2023522198A publication Critical patent/JP2023522198A/ja
Publication of JP2023522198A5 publication Critical patent/JP2023522198A5/ja
Publication of JPWO2021212123A5 publication Critical patent/JPWO2021212123A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022562788A 2020-04-17 2021-04-19 黒色腫を治療するためのｃｔｌ抗原の融合タンパク質 Pending JP2023522198A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20170174.5 2020-04-17
EP20170174 2020-04-17
PCT/US2021/028029 WO2021212123A1 (en) 2020-04-17 2021-04-19 Fusion proteins of ctl antigens for treating melanoma

Publications (3)

Publication Number Publication Date
JP2023522198A true JP2023522198A (ja) 2023-05-29
JP2023522198A5 JP2023522198A5 (https=) 2024-05-20
JPWO2021212123A5 JPWO2021212123A5 (https=) 2024-05-20

Family

ID=70295067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562788A Pending JP2023522198A (ja) 2020-04-17 2021-04-19 黒色腫を治療するためのｃｔｌ抗原の融合タンパク質

Country Status (6)

Country Link
US (1) US20230167163A1 (https=)
EP (1) EP4136097A1 (https=)
JP (1) JP2023522198A (https=)
CN (1) CN116057067A (https=)
CA (1) CA3179694A1 (https=)
WO (1) WO2021212123A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021005338A2 (en) * 2019-07-05 2021-01-14 The Francis Crick Institute Limited Novel cancer antigens and methods
JP2023522193A (ja) * 2020-04-17 2023-05-29 ザ フランシス クリック インスティチュート リミティッド 抗原プール
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099750A1 (en) * 2004-04-16 2005-10-27 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Vaccination against malignant melanoma using bcg and/or vaccinia
WO2006119527A2 (en) * 2005-05-11 2006-11-16 Avir Green Hills Biotechnology Research Development Trade Ag Melanoma-associated endogenous retrovirus (merv) derived peptide sequences and their therapeutic/ diagnostic use
US20070083334A1 (en) * 2001-09-14 2007-04-12 Compugen Ltd. Methods and systems for annotating biomolecular sequences
JP2022514116A (ja) * 2018-10-19 2022-02-09 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法
JP2022540396A (ja) * 2019-07-05 2022-09-15 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1053325E (pt) * 1998-02-05 2006-05-31 Glaxosmithkline Biolog Sa Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
CN100419079C (zh) * 1998-07-14 2008-09-17 科里克萨有限公司 用于治疗和诊断前列腺癌的组合物和方法
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
DK1871391T3 (da) 2005-03-30 2012-04-16 Viroxis Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
CN101638440B (zh) * 2008-07-29 2011-10-26 中国人民解放军军事医学科学院基础医学研究所 一种可诱发机体抗肿瘤免疫的异种抗原-Fc融合蛋白及其应用
AU2020302285A1 (en) * 2019-06-28 2021-12-02 Enara Bio Limited Novel cancer antigens and methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070083334A1 (en) * 2001-09-14 2007-04-12 Compugen Ltd. Methods and systems for annotating biomolecular sequences
WO2005099750A1 (en) * 2004-04-16 2005-10-27 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Vaccination against malignant melanoma using bcg and/or vaccinia
WO2006119527A2 (en) * 2005-05-11 2006-11-16 Avir Green Hills Biotechnology Research Development Trade Ag Melanoma-associated endogenous retrovirus (merv) derived peptide sequences and their therapeutic/ diagnostic use
JP2022514116A (ja) * 2018-10-19 2022-02-09 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法
JP2022540396A (ja) * 2019-07-05 2022-09-15 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BMC CANCER, vol. 13, JPN6025010676, 2013, pages 4, ISSN: 0005552630 *
CANCER RESEARCH, vol. 62, JPN6025010675, 2002, pages 5510 - 5516, ISSN: 0005552629 *
GENOME RESEARCH, vol. 29, JPN6025010674, 2019, pages 1578 - 1590, ISSN: 0005692711 *

Also Published As

Publication number Publication date
WO2021212123A1 (en) 2021-10-21
US20230167163A1 (en) 2023-06-01
EP4136097A1 (en) 2023-02-22
CN116057067A (zh) 2023-05-02
CA3179694A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
JP7762132B2 (ja) 新規な癌抗原及び方法
US20230167163A1 (en) Fusion proteins of ctl antigens for treating melanoma
JP2025032114A (ja) 新規な癌抗原及び方法
JP7751817B2 (ja) 新規な癌抗原及び方法
US20220211760A1 (en) Novel cancer antigens and methods
JP2022539157A (ja) 新規な癌抗原及び方法
US20230302109A1 (en) Antigen pool
EA052067B1 (ru) Новые раковые антигены и сопутствующие способы
EA052615B1 (ru) Новые раковые антигены и сопутствующие способы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240508

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250617

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260121